Compass Therapeutics (CMPX) Income from Continuing Operations (2023 - 2025)
Historic Income from Continuing Operations for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to -$15.8 million.
- Compass Therapeutics' Income from Continuing Operations fell 2923.44% to -$15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$70.1 million, marking a year-over-year decrease of 4154.73%. This contributed to the annual value of -$56.6 million for FY2024, which is 3325.41% down from last year.
- According to the latest figures from Q3 2025, Compass Therapeutics' Income from Continuing Operations is -$15.8 million, which was down 2923.44% from -$21.1 million recorded in Q2 2025.
- Compass Therapeutics' Income from Continuing Operations' 5-year high stood at -$7.8 million during Q1 2023, with a 5-year trough of -$21.1 million in Q2 2025.
- For the 3-year period, Compass Therapeutics' Income from Continuing Operations averaged around -$13.5 million, with its median value being -$13.1 million (2024).
- As far as peak fluctuations go, Compass Therapeutics' Income from Continuing Operations crashed by 1594.25% in 2024, and later plummeted by 6110.43% in 2025.
- Quarter analysis of 3 years shows Compass Therapeutics' Income from Continuing Operations stood at -$13.4 million in 2023, then fell by 23.55% to -$16.6 million in 2024, then increased by 4.57% to -$15.8 million in 2025.
- Its last three reported values are -$15.8 million in Q3 2025, -$21.1 million for Q2 2025, and -$16.6 million during Q1 2025.